Immediate Impact
70 standout
Citing Papers
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
2025 Standout
Breast cancer: pathogenesis and treatments
2025 Standout
Works of Alison Timm being referenced
Abstract CT017: Pan-mutant and isoform selective PI3Kα inhibitor, RLY-2608, demonstrates selective targeting in a first-in-human study of PIK3CA-mutant solid tumor patients, ReDiscover trial
2023
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Alison Timm | 101 | 140 | 34 | 67 | 14 | 307 | |
| Olu Oyesanmi | 21 | 119 | 21 | 30 | 17 | 330 | |
| Chloe Tolley | 37 | 47 | 25 | 27 | 24 | 310 | |
| Matthew Welch | 37 | 88 | 6 | 42 | 22 | 357 | |
| Wendy Chow | 52 | 40 | 84 | 27 | 22 | 367 | |
| Dylan R. Rice | 45 | 29 | 18 | 17 | 23 | 333 | |
| Vish Viswanath | 74 | 92 | 41 | 28 | 12 | 310 | |
| Krista Herbert | 26 | 111 | 71 | 75 | 11 | 274 | |
| Annetine Staff | 36 | 58 | 133 | 10 | 13 | 309 | |
| Louise Heuzenroeder | 30 | 42 | 35 | 16 | 10 | 346 | |
| Ashley Nelson | 12 | 147 | 37 | 37 | 16 | 280 |
All Works
Loading papers...